|Mr. John M. Evans M.B.A.||CEO & Director||1.02M||1.62M||1978|
|Dr. Giuseppe Ciaramella Ph.D.||Pres & Chief Scientific Officer||890.79k||14.85M||1969|
|Ms. Terry-Ann Burrell M.B.A.||CFO & Treasurer||687.52k||9.18M||1977|
|Dr. Feng Zhang Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. David R. Liu Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. J. Keith Joung M.D., Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Nicole Gaudelli Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Alexis Komor Ph.D.||Co-Founder||N/A||N/A||N/A|
|Ms. Suzanne Fleming||Chief Accounting Officer||N/A||N/A||1961|
|Mr. Brian Riley||Sr. VP of Technical Operations||N/A||N/A||1977|
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Beam Therapeutics Inc.’s ISS governance QualityScore as of 1 June 2022 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 6; Compensation: 8.